TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02910518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (U300)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Pharmaceutical form: solution~Route of administration: intravenous/subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Pharmaceutical form: solution~Route of administration: intravenous/subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH insulin
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Pharmaceutical form: Powder and solvent for solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Pharmaceutical form: Powder and solvent for solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Pharmaceutical form: solution~Route of administration: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Pharmaceutical form: solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Pharmaceutical form: solution~Route of administration: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Pharmaceutical form: solution~Route of administration: intravenous
Study: NCT00933842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Treatment duration: 5 weeks
Study: NCT03289481

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active lozenge
Description: nitric oxide generating lozenge

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active lozenge
Description: nitric oxide generating lozenge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo tablet
Study: NCT04472780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen Therapy HBOT
Description: HBOT therapy protocol: in an eight-seat hyperbaric chamber 40 sessions of HBOT duration: 1 hour rhythm: 5 sessions / week pressure: 1.7 ATA (7 meters) O2 concentration: 100%
Study: NCT03935217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secnidazole
Description: Oral Granules containing secnidazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Granules of placebo manufactured to mimic secnidazole
Study: NCT00259376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone (SR33589)
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral administration
Study: NCT01992549

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human-cl rhFVIII
Study: NCT04198740

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear sample collection via Schirmer strip and subsequent analysis by mass spectrometry
Description: During regular consultations at the ophthalmology department of the CHUM, eligible patients will undergo a standard 5 minute Schirmer tear test. The Schirmer strips will serve as tear samples and will be sent to UQAM's Department of chemistry for mass spectrometry analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear sample collection via Schirmer strip and subsequent analysis by mass spectrometry
Description: During regular consultations at the ophthalmology department of the CHUM, eligible patients will undergo a standard 5 minute Schirmer tear test. The Schirmer strips will serve as tear samples and will be sent to UQAM's Department of chemistry for mass spectrometry analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear sample collection via Schirmer strip and subsequent analysis by mass spectrometry
Description: During regular consultations at the ophthalmology department of the CHUM, eligible patients will undergo a standard 5 minute Schirmer tear test. The Schirmer strips will serve as tear samples and will be sent to UQAM's Department of chemistry for mass spectrometry analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear sample collection via Schirmer strip and subsequent analysis by mass spectrometry
Description: During regular consultations at the ophthalmology department of the CHUM, eligible patients will undergo a standard 5 minute Schirmer tear test. The Schirmer strips will serve as tear samples and will be sent to UQAM's Department of chemistry for mass spectrometry analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear sample collection via Schirmer strip and subsequent analysis by mass spectrometry
Description: During regular consultations at the ophthalmology department of the CHUM, eligible patients will undergo a standard 5 minute Schirmer tear test. The Schirmer strips will serve as tear samples and will be sent to UQAM's Department of chemistry for mass spectrometry analysis.
Study: NCT03507543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297
Description: The dose levels will be escalated following a modified 3+3 dose escalation scheme.
Study: NCT00268931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement Training
Description: This group of infants underwent specific movement training activities two times per day with their parents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Training
Description: This group underwent special social interactions with their parents two times each day.
Study: NCT00896129

Intervention type: OTHER
Intervention: HRQOL Survey Packet
Description: Questionnaires
Study: NCT05980429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy, prescribed
Description: All music pieces selected for the prescribed intervention contain compositional elements of relaxation analyzed, prepared, and recorded by professional concert artists and a Grammy-nominated composer. The compositional elements included Accentuation, Articulation, Dynamic Range, Familiarity, Interpretive Expertise, Melodic Shape, Meter, Recording Quality, Repetition, Register, Rubato, Tempo, Texture, Timbre, Transition, and Tonality. These 15 repertoire-selecting parameters were used to choose the prescribed music play list for this study. Music used for the study was downloaded from a password-protected Google Drive accessible to the study participants assigned to the prescribed music intervention group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy, self-selected
Description: All music pieces were self-selected by the participant
Study: NCT04444375

Intervention type: DIAGNOSTIC_TEST
Intervention: balance test
Description: balance test
Study: NCT03765463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Reversal Training
Description: 4 sessions of habit reversal training
Study: NCT02044237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decoupling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive relaxation
Study: NCT00991159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RN316
Description: Single, escalating doses of RN316 administered IV. Doses planned for testing = 0.3, 1.0, 3.0, 6.0, 12.0, and 18.0 mg/kg.
Study: NCT00808899

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid
Description: 13-cis-retinoic acid
Study: NCT02547597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Study: NCT01687868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine 0.7mcg/kg/hr continuous infusion
Study: NCT00099203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bondronat]
Description: 6mg iv on days 1-3, and every 3-4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: 4mg iv on day 1 and every 3-4 weeks
Study: NCT03181282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Postural stability exercises will follow a framework targeting quiet stance, anticipatory and reactive postural adjustments, and dynamic postural control. Gait exercises will include treadmill walking and practice with dual-task gait. A home exercise program (HEP), to be completed twice weekly, will be provided on each participant's initial visit with the physical therapist following STN-DBS surgery. The HEP will include the following exercises: trunk rotation, standing hip flexion, standing hip abduction, standing plantarflexion, and standing squat.
Study: NCT02413606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced follow-up schedule
Description: In the intervention group, the follow-up schedule will be limited to four follow-up visits at 3, 12, 24 and 36 months, under the specific condition that patients have easy and prompt access to care (specialised nurse of gynaecologist) if symptoms or questions occur. The content of the follow-up visits will be similar for both groups.
Study: NCT03561597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile health intervention
Description: The Kurbo program is a multifunctional mobile application that aid adolescents and their families to learn healthy eating habits and weight management through the use of a mobile application with dietary self-monitoring and weekly interactive coaching sessions. Using the Kurbo app, adolescents track their food and exercise, as well as learn about healthy behaviours through games and videos. The Kurbo coaches check in with adolescents for 15 minutes once a week via video, phone or text over a 12 weeks period.
Study: NCT04297072

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY-597939)
Description: Non-vitamin K antagonist oral anticoagulants (NOACs). The prescription of drug is at the discretion of physician following the routine clinical practice.

Intervention type: DRUG
Intervention: VKAs
Description: Oral anticoagulant. The prescription of drug is at the discretion of physician following the routine clinical practice.
Study: NCT00573651

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Draws for Serum Titers
Description: All study subjects are receiving the Gardasil vaccine as part of their clinical care. The Gardasil vaccine is not given because of study participation. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers. Other study specific procedures performed include Questionnaires and observational data.
Study: NCT00331708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate plus sulfadoxine-pyrimethamine
Study: NCT03765164

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GlycoMark 1-5-AG
Description: Online educational materials on GlycoMark 1,5-AG and sample test results for simulated patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Performance and Value Vignettes
Description: Simulated diabetic patients cared for online

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Performance and Value Vignettes
Description: Simulated diabetic patients cared for online
Study: NCT02484547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab (BIIB037)
Description: Low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab (BIIB037)
Description: High dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01351337

Intervention type: PROCEDURE
Group type: OTHER
Intervention: diffusion tensor tractography neuronavigation and intraoperative subcortical stimulation
Description: All of the patients underwent tumor resection assisted with combined use of Diffusion tensor tractography-integrated functional neuronavigation and intraoperative subcortical stimulation
Study: NCT02894905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: Participants with various degrees of impaired renal function (mild \[Cohort 1\], moderate \[Cohort 2\], severe \[Cohort 3\]) and normal renal function (Cohort 4) will receive a single oral dose of AL-335 800 mg (given as 2\*400-mg tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: Participants with various degrees of impaired renal function (mild \[Cohort 1\], moderate \[Cohort 2\], severe \[Cohort 3\]) and normal renal function (Cohort 4) will receive a single oral dose of AL-335 800 mg (given as 2\*400-mg tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: Participants with various degrees of impaired renal function (mild \[Cohort 1\], moderate \[Cohort 2\], severe \[Cohort 3\]) and normal renal function (Cohort 4) will receive a single oral dose of AL-335 800 mg (given as 2\*400-mg tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: Participants with various degrees of impaired renal function (mild \[Cohort 1\], moderate \[Cohort 2\], severe \[Cohort 3\]) and normal renal function (Cohort 4) will receive a single oral dose of AL-335 800 mg (given as 2\*400-mg tablets).
Study: NCT00815919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given intravenously at a dose of 1.3 mg/m\^2 once a week for the first four weeks of a five week cycle for a total of 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Taken orally once a day at a dose of 0.5-1 mg/kg. Dose reduction may be initiated after 1 cycle of therapy. A suggested taper is 10-25% every 1-2 weeks.
Study: NCT05930132

Intervention type: PROCEDURE
Group type: OTHER
Intervention: submucosal conchoplasty
Description: Regarding the submucosal conchoplasty technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000. The mucosa was incised by blade 15 starting from the axilla posteriorly up to the attachment with the basal lamella. The mucosa covering the lateral lamella was dissected using the freer dissector. The lateral lamella was removed using a through cut forceps then the mucosa was repositioned. The bony skeleton of the medial lamella was preserved

Intervention type: PROCEDURE
Group type: OTHER
Intervention: classic lateral lamellectomy
Description: Regarding the lateral lamellectomy technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000; the sickle knife was used to open the concha then the scissor was used to remove the lateral lamella with its covering mucosa in one block.~No middle meatus packing was applied. Systemic antibiotics and steroids (0.5 mg / kg prednisolone) were given for two weeks after the surgery. The patients were instructed to use local nasal irrigations (2 ml of budesonide 0.5 mg / ml mixed with 250 ml of normal saline) two times daily for a month postoperatively. Patients were followed up at the end of each month throughout the six months follow-up period.
Study: NCT00546078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: Intramuscular injection, one or three doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: Intramuscular injection, one or three doses
Study: NCT00814645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrite Inhalation Solution
Description: a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrite Inhalation Solution
Description: a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrite Inhalation Solution
Description: a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrite Inhalation Solution
Description: a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and AIR001 Inhalation Solution (Expansion arm)
Description: On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
Study: NCT04637516

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Animation program BlinkBlink
Description: Computer program that presents horizontal bars on the computer screen that move from above and below towards each other, mimicking a blink movement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Animation program BlinkBlink
Description: Computer program that presents horizontal bars on the computer screen that move from above and below towards each other, mimicking a blink movement.
Study: NCT04440059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: ICP-022 at a dose of 150mg PO QD
Study: NCT01058083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Active, Oral, 15 mg, Daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Active, Oral, 50 mg, Daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Active, Oral, 150 mg, Daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-770767
Description: Active, Oral, 50 mg BID, Daily, 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Oral, 0 mg, daily, 28 days
Study: NCT01951521

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost
Description: External Beam radiation delivered using intensity modulation radiation therapy (IMRT) planning, consisting of 15 Gy (in 5 sequential fractions).
Study: NCT05523856

Intervention type: PROCEDURE
Intervention: Active Surveillance
Description: It consists on monitoring the cancer with regular tests including PSA, blood test and digital rectal examination every 6 months, a magnetic resonance imaging and prostate biopsy at the first year, and based on clinical decision thereafter. If there was a change on the results, the patient is considered for treatment.

Intervention type: PROCEDURE
Intervention: Robot-Assisted Radical Prostatectomy
Description: It consists on the removal of the prostate gland and seminal vesicles with neurovascular preservation whenever anatomically and oncologically possible, with the Da Vinci procedure. Access is made through 5 or 6 small incisions, less than 1 cm. An extended pelvic lymph node dissection is performed when the risk estimation of node involvement is above the 5%. After surgery, the patient will be hospitalized for about 3 days and will probably resume his work activity between 3 and 5 weeks.

Intervention type: RADIATION
Intervention: Intensity-Modulated Radiotherapy
Description: Patients in this group undergo volumetric modulated arc therapy under daily image-guided radiation therapy in the supine position. Radiation is delivered in 2-3 Gy daily fractions, 5 days per week, with a prescription dose of 60-70 Gy to the prostate.

Intervention type: RADIATION
Intervention: Real-time brachytherapy
Description: Patients in this group receive I125 permanent seeds (low dose rate). The images are obtained with a transrectal ultrasound probe and are transferred to a planning system for calculating the number and position of the seeds. The prescrption dose is 145 Gy to the reference isodose (100%).
Study: NCT01214681

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin and Amioca starch
Description: 12g Maltodextrin and 23g Amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hi-maize 260
Description: 23g Hi-maize 260 and 12g Maltodextrin daily in divided doses for 50 days. Provided as a powder to be added to food or drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polydextrose
Description: 12g polydextrose and 23g amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hi-maize 260 and polydextrose
Description: 12g polydextrose and 23g Hi-maize 260 daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
Study: NCT03437161

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Undergo RT either in the supine position with DIBH or in the prone position.
Study: NCT02850718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Sildenafil
Description: 50 mg sildenafil sublingual wafer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sildenafil
Description: 50 mg oral sildenafil (Viagra)
Study: NCT02291809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMUNE
Description: Inoculation of HIV-1 Virus via Vaccination of Whole Killed GP120 Depleted P24 Antigen Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: REMUNE
Description: Inoculation of HIV-1 Virus via Vaccination of Whole Killed GP120 Depleted P24 Antigen Vaccine
Study: NCT03167047

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: Caudal epidural

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block
Description: Peripheral nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standarising intraoperative pain relief
Description: All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standarising intraoperative pain relief
Description: All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.
Study: NCT02325830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carillon Mitral Contour System
Description: Percutaneous mitral valve repair
Study: NCT00428025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac
Description: 100 mg diclofenac rectal suppository

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: similar shape and size suppository